Back to Interventions
Substance / Medication

Imipramine hydrochloride

SNOMED 3378009UMLS C0589978

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Depressive disorder
Panic disorder
Attention deficit hyperactivity disorder
Affective psychosis

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Calcidiol+ercalcidiol

LOINC 14635-7

secondary

Cobalamins

LOINC 2132-9

secondary

Thyrotropin

LOINC 3016-3

secondary

Clinical Trials

48 trials linked to this intervention

48
Total Trials
5
Recruiting
17
With Results

Recent Trials

Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive Disorder

NCT00000375Phase 4Completed

Antidepressant Treatment of Melancholia in Late Life

NCT00000378Phase 4Completed110 enrolled

Optimizing Electroconvulsive Therapy for Depression

NCT00045916Phase 4Completed340 enrolled

Ethnic Variations in Antidepressant Response

NCT00047671Phase 4Completed400 enrolled

Research Evaluating the Value of Augmenting Medication With Psychotherapy

NCT00057551Phase 4Completed491 enrolled
View all 48 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Effects of imipramine hydrochloride on the EEG of children with Attention-Deficit/Hyperactivity Disorder who are non-responsive to stimulants.
Clarke Adam R, Barry Robert J, McCarthy Rory et al. · Int J Psychophysiol · 2008
PMID: 18304665RCT
Transdermal delivery of imipramine hydrochloride: development and evaluation (in vitro and in vivo) of reservoir gel formulation.
Jain Amit Kumar, Panchagnula Ramesh · Biopharm Drug Dispos · 2005
PMID: 15614831Observational
In silico toxicity assessment and trace level quantification of potential genotoxic impurities in imipramine hydrochloride.
Nalawade Vighnesh Pradeep, Kulkarni Ravindra, Sayyed Faiz Hussain et al. · Toxicol Lett · 2025
PMID: 40774614Other
Chitosan Nanoparticles Embedded in In Situ Gel for Nasal Delivery of Imipramine Hydrochloride: Short-Term Stage Development and Controlled Release Evaluation.
Adwan Samer, Obeidi Teiba, Al-Akayleh Faisal · Polymers (Basel) · 2024
PMID: 39518270OtherFull text (PMC)
FeSnanosheets-luminol-Ochemiluminescence method for determination of venlafaxine hydrochloride, imipramine hydrochloride, and cefazolin sodium.
Iranifam Mortaza, Royan Maryam, Golshani Pariya et al. · Luminescence · 2024
PMID: 38644416Other
Interaction of TX-100 and Antidepressant Imipramine Hydrochloride Drug Mixture: Surface Tension,H NMR, and FT-IR Investigation.
Rub Malik Abdul, Azum Naved, Kumar Dileep et al. · Gels · 2022
PMID: 35323272OtherFull text (PMC)
Effects of various media on micellization, adsorption and thermodynamic behaviour of imipramine hydrochloride and antimicrobial surfactant mixtures.
Alghamdi Yousef G, Rub Malik Abdul, Kumar Dileep et al. · R Soc Open Sci · 2021
PMID: 34950495OtherFull text (PMC)
Investigation of Solution Behavior of Antidepressant Imipramine Hydrochloride Drug and Non-Ionic Surfactant Mixture: Experimental and Theoretical Study.
Rub Malik Abdul, Azum Naved, Kumar Dileep et al. · Polymers (Basel) · 2021
PMID: 34833323OtherFull text (PMC)
Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend SF PH4 oral suspensions.
Polonini H C, Silva S L, Cunha C N et al. · Pharmazie · 2016
PMID: 27209697Other
A spectrophotometric assay method for vanadium in biological and environmental samples using 2,4-dinitrophenylhydrazine with imipramine hydrochloride.
Al-Tayar Naef Ghllab Saeed, Nagaraja P, Vasantha R A et al. · Environ Monit Assess · 2012
PMID: 21625927Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Internal Medicine Physician

Internal Medicine

NUCC 207R00000X
Psychiatry Physician

Psychiatry & Neurology — Psychiatry

NUCC 2084P0800X
Find a Provider

Health Goals

Goals connected through associated conditions

Support Mental Wellness

Quick Facts

Type
Substance / Medication
Fully Specified Name
Imipramine hydrochloride (substance)
SNOMED CT
3378009
UMLS CUI
C0589978

Clinical Data

This intervention maps to 10 entities in the Ltrl knowledge graph.

4
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
48
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.